Posted innews
Evolocumab 预防高风险患者首次发生主要心血管事件
在 VESALIUS-CV 研究中，与安慰剂相比，evolocumab 将无既往心肌梗死或卒中的动脉粥样硬化或糖尿病患者的首次主要不良心血管事件减少了约 25%（HR 0.75），绝对风险降低幅度较小，随访 4.6 年未发现新的安全性信号。
Posted inCardiology Diabetes & Endocrinology news
Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke
In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.